Paridiprubart is a Monoclonal Antibody owned by Edesa Biotech, and is involved in 5 clinical trials, of which 3 were completed, and 2 are ongoing.

EB-05 (NI-0101) acts as toll-like receptor 4 (TLR4) antagonist. NI-0101 binds to an epitope on TLR4 which interferes with its dimerization required for intracellular signaling and induction of numerous pro-inflammatory pathways. TLR4 activates NF-kappa B-dependent transcription of inflammatory cytokine genes in the diseased condition. The drug candidate blocks at the level of signal transduction for any ligand source and treats the condition.

The revenue for Paridiprubart is expected to reach a total of $133m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Paridiprubart NPV Report.

Paridiprubart was originated by Light Chain Bioscience and is currently owned by Edesa Biotech.

Paridiprubart Overview

EB-05 (NI-0101) is under development for the treatment of allergic contact dermatitis, acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and unspecified disease. The drug candidate is administered intravenously. It is a humanized monoclonal antibody (mAb) targeting human Toll-like receptor 4 (TLR4). It was under development for the treatment of rheumatoid arthritis.

Edesa Biotech Overview

Edesa Biotech is a clinical-stage biopharmaceutical and healthcare company, which focuses on the development of gastrointestinal and dermatological diseases, including alternatives to topical steroids. The company’s clinical product pipeline includes EB01, which is a novel sPLA2 inhibitor (non-steroidal anti-inflammatory molecule) for the topical treatment of chronic allergic contact dermatitis (ACD) and EB02, which is a novel sPLA2 inhibitor for the treatment of hemorrhoids in adults. In addition, its two lead product candidates, EB01 and EB05 are in clinical studies. Edesa Biotech’s EB05 product is a monoclonal antibody therapy that we are developing as a treatment for Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients. It has operations in Canada and the US. Edesa Biotech is headquartered in Markham, Ontario, Canada.

The operating loss of the company was US$23.7 million in FY2021, compared to an operating loss of US$6.4 million in FY2020. The net loss of the company was US$13.3 million in FY2021, compared to a net loss of US$6.4 million in FY2020.

Quick View – Paridiprubart

Report Segments
  • Innovator
Drug Name
  • Paridiprubart
Administration Pathway
  • Intravenous
  • Intravenous Drip
Therapeutic Areas
  • Dermatology
  • Immunology
  • Infectious Disease
  • Undisclosed
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.